Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Pursuit of Biomarkers for CDK4/CDK6 Response Fails

TOP - August 2017, Vol 10, No 3 - AACR News, Conference Correspondent
Phoebe Starr

Washington, DC—Palbociclib and ribociclib are 2 cyclin-dependent kinase (CDK)4/6 inhibitors approved by the FDA for the treatment of patients with hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer. A third CDK4/CDK6 inhibitor, abemaciclib, is currently in phase 3 clinical trials, and other drugs in this class are in varying stages of development. As these drugs are introduced into the clinic, an active area of research is the identification of biomarkers for response that would inform oncologists about which patients are likely to respond.

Thus far, investigators have come up empty in the search for response biomarkers. At the 2017 meeting of the American Association for Cancer Research (AACR), an analysis of patients enrolled in MONALEESA-2, a phase 3 clinical trial of ribociclib (an orally available CDK4/CDK6 inhibitor) plus letrozole versus letrozole alone failed to identify a biomarker for response to ribociclib.

MONALEESA-2 enrolled 668 postmenopausal women with HR+/HER2– advanced breast cancer who had received no previous therapy. Women were randomized 1:1 to letrozole plus ribociclib versus letrozole plus placebo. Fifty-nine percent of the population had visceral metastases. Archival tumor tissue was required at study entry, and biomarkers were part of an exploratory end point of the trial.

Results showed that ribociclib plus letrozole improved progression-free survival versus letrozole alone. Median progression-free survival was not reached in the ribociclib-containing arm, and was 14.3 months for letrozole alone.

Fresh or archival tumor tissue was used in the study of the first set of biomarkers. At the AACR meeting, lead investigator Fabrice André, MD, PhD, Professor, Medical Oncology, Institut Gustave Roussy, Villejuif, France, reported on results with 6 biomarkers, such as expression of Rb, p16, and Ki67 protein levels, and CDKN2A, CCND1, and ESR1 gene expression levels. Tumor samples were available as follows: 479 samples for Rb, 405 for p16, 463 for Ki67, and 386 samples for CDKN2A, CCND1, and ESR1 gene expression. The investigators also looked at progression-free survival according to PIK3CA expression in circulating DNA.

Ribociclib plus letrozole was consistently more effective than letrozole, but no differential effect of ribociclib was observed according to any of the biomarkers studied. Additional biomarkers will be studied, Dr André said.

Audience member Hope S. Rugo, MD, Director, Breast Oncology Clinical Trials Program, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, and lead investigator of the MONARCH-1 study of abemaciclib, asked Dr André whether changes in these markers over the course of disease could be a partial explanation of the inability to identify a biomarker for ribociclib.

“That could be one of the explanations. I personally believe that the usual strategies to find predictive biomarkers for CDK4/6 will fail. It is possible that we need to detect subclonal changes in expression with a phosphoprotein assay as a first step,” Dr André said.

Filipa Lynce, MD, Medical Oncologist, Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, said biomarkers are needed to identify nonresponders and patients who can be treated with endocrine therapy alone.

“In MONALEESA-2, progression-free survival was better with ribociclib, but the investigators failed to identify a subgroup of patients who can benefit. Perhaps it would be better to study patients with primary resistance or those who will do well on endocrine therapy alone,” she suggested.

Related Items
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Renal-Cell Carcinoma
Darolutamide, New Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in High-Risk Prostate Cancer
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Prostate Cancer
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Leukemia
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Emerging Therapies
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Emerging Therapies
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Breast Cancer
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Prostate Cancer
Last modified: August 2, 2017